Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

BACKGROUND: Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited. CASE: A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the combination of pembrolizumab, a PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: McNamara, Blair, Bellone, Stefania, Demirkiran, Cem, Max Philipp Hartwich, Tobias, Santin, Alessandro D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Survey Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265468/
https://www.ncbi.nlm.nih.gov/pubmed/37325296
http://dx.doi.org/10.1016/j.gore.2023.101218
Descripción
Sumario:BACKGROUND: Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited. CASE: A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the combination of pembrolizumab, a PD-1 targeting monoclonal antibody and lenvatinib, an oral multikinase inhibitor, after failing standard and experimental treatments. She experienced a 40.1% reduction of target lesions over 26 weeks of therapy. CA-125 trends confirmed serial CT scan findings of shrinking disease burden. She experienced overall mild side effects from the drug combination, and lenvatinib dosage was decreased from 20 to 10 mg/day over her 10 cycles. CONCLUSION: The combination of pembrolizumab and lenvatinib may represent a new treatment option for chemotherapy-resistant ovarian CCC.

Ejemplares similares